AcelRx Pharmaceuticals (ACRX)
Add to Watchlists Create an Alert
7.29
+0.89 +13.91%
NASDAQ
May 22, 4:59PM
BATS Real time
Currency in USD
Pro Data Export
AcelRx Pharmaceuticals Key Statistics
Currency in USD
Current Valuation
Dividends and Shares
| Shares Outstanding | 37.24M |
| Dividend | |
| Dividend Yield | 0.00% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Latest Dividend Date | |
| Latest Ex-Dividend Date | |
| Last Split Factor | |
| Last Split Date |
Profitability
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | -628.2% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 4.31 |
| Debt to Equity Ratio | 0.4719 |
| Free Cash Flow | -5.902M |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | 24.40% |
| Year to Date Stock Returns | 71.13% |
| 1 Year Stock Returns | 111.3% |
| 3 Year Stock Returns | |
| 52 Week High | 7.420 |
| 52 Week Low | 2.27 |
Income Statement
Cash Flow Statement
| Cash from Financing TTM | 49.76M |
| Cash from Investing TTM | 14.96M |
| Cash from Operations TTM | -24.58M |
| Capital Expenditures Quarterly Pro | Go Pro |
Balance Sheet
| Cash and ST Investments | 59.76M |
| Long Term Debt | 15.97M |
| Total Assets | 64.52M |
| Liabilities | 30.67M |
| Shareholders Equity | 33.85M |
| Book Value | 33.85M |
| Book Value Per Share | 0.909 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
ACRX News
AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
Street Insider May 21
Street Insider May 21
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACRX | 7.29 | +0.89 | +13.91% | 271.46M |
New watchlist
